The effects of liraglutide on glucose, inflammatorymarkersandlipoprotein metabolism: current knowledge and future perspective

References

• Kazafeos K. Incretin effect: GLP-1, GIP, DPP4. Diabetes Res. Clin. Pract. 93(Suppl. 1), S32–S36 (2011).
   Google Scholar
• Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 375(9712), 408–418 (2010).
   Google Scholar
• Chan JC, Malik V, Jia W et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301(20), 2129–2140 (2009).
   Google Scholar
• Blonde L. Current antihyperglycemic treatment strategies for patients with Type 2 diabetes mellitus. Cleve. Clin. J. Med. 76(Suppl. 5), S4–S11 (2009).
   Google Scholar
• Barnett AH. New treatments in Type 2 diabetes: a focus on the incretin-based therapies. Clin. Endocrinol. 70(3), 343–353 (2009).
   Google Scholar
• Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin based therapies for Type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr. Diabetes Rev. 4(2), 101–109 (2008).
   Google Scholar
• Knudsen LB, Nielsen PF, Huusfeldt PO et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J. Med. Chem. 43(9), 1664–1669 (2000).
   Google Scholar
• Verspohl EJ. Novel therapeutics for Type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacol. Ther. 124(1), 113–138 (2009).
   Google Scholar
• Nauck MA, El-Ouaghlidi A, Hompesch M, Jacobson J, Bodil E. No impairment of hypoglycemia counter regulation via glucagon with NN2211, a GLP-1 derivative, in subjects with Type 2 diabetes. Diabetes 52(Suppl. 1), A128 (2003).
   Google Scholar
• Horowitz M, Flint A, Jones KL et al. Effect of the once-daily human GLP-1 analogue liraglutide on appetite, energy intake, energy expenditure and gastric emptying in Type 2 diabetes. Diabetes Res. Clin. Pract. 97(2), 258–266 (2012).
   Google Scholar
• Degn KB, Juhl CB, Sturis J et al. One week’s treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alphaand beta-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes 53(5), 1187–1194 (2004).
   Google Scholar
• Bregenholt S, Moldrup A, Blume N et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits beta-cell apoptosis in vitro. Biochem. Biophys. Res. Comm. 330(2), 577–584 (2005).
   Google Scholar
• Jacobsen LV, Hindsberger C, Robson R, Zdravkovic M. Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide. Br. J. Clin. Pharmacol. 68(6), 898–905 (2009).
   Google Scholar
• Flint A, Nazzal K, Jagielski P, Hindsberger C, Zdravkovic M. Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide. Br. J. Clin. Pharmacol. 70(6), 807–814 (2010).
   Google Scholar
• Neumiller JJ, Sonnett TE, Wood LD, Setter SM, Campbell RK. Pharmacology, efficacy and safety of liraglutide in the management of Type 2 diabetes. Diabetes Metab. Syndr. Obes. 3, 215–226 (2010).
   Google Scholar
• Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45(2), 195–202 (2002).
   Google Scholar
• Valentine WJ, Palmer AJ, Lammert M, Langer J, Brandle M. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with Type 2 diabetes who fail to improve with oral antidiabetic agents. Clin. Ther. 33(11), 1698–1712 (2011). Evaluates the long-term cost–effectiveness of liraglutide versus exenatide.
   Google Scholar
• Pinelli NR, Hurren KM. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in Type 2 diabetes mellitus: a systematic review and meta-analysis. Ann. Pharmacother. 45(7–8), 850–860 (2011).
   Google Scholar
• Jespersen MJ, Knop FK, Christensen M. GLP-1 agonists for Type 2 diabetes: pharmacokinetic and toxicological considerations. Expert Opin. Drug Metab. Toxicol. 9(1), 17–29 (2013).
   Google Scholar
• Marre M, Shaw J, Brandle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Med. 26(3), 268–278 (2009).
   Google Scholar
• Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373(9662), 473–481 (2009).
   Google Scholar
• Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in Type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32(1), 84–90 (2009).
   Google Scholar
• Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with Type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 32(7), 1224–1230 (2009).
   Google Scholar
• Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in Type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 52(10), 2046–2055 (2009).
   Google Scholar
• Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for Type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683), 39–47 (2009).
   Google Scholar
• Seino Y, Rasmussen MF, Zdravkovic M, Kaku K. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with Type 2 diabetes. Diabetes Res. Clin. Pract. 81(2), 161–168 (2008).
   Google Scholar
• Pratley RE, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with Type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 375(9724), 1447–1456 (2010).
   Google Scholar
• Mori Y, Taniguchi Y, Sezaki K, Yokoyama J, Utsunomiya K. Liraglutide narrows the range of circadian glycemic variations in Japanese Type 2 diabetes patients and nearly flattens these variations in drug-naive Type 2 diabetes patients: a continuous glucose monitoringbased study. Diabetes Tech. Ther. 13(11), 1139–1144 (2011).
   Google Scholar
• Seino Y, Rasmussen MF, Nishida T, Kaku K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with Type 2 diabetes. Curr. Med. Res. Opin. 26(5), 1013–1022 (2010).
   Google Scholar
• Yang W, Chen L, Ji Q et al. Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with Type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial. Diabetes Obes. Metab. 13(1), 81–88 (2011).
   Google Scholar
• Chaudhuri A, Ghanim H, Vora M et al. Exenatide exerts a potent antiinflammatory effect. J. Clin. Endocrinol. Metab. 97(1), 198–207 (2012).
   Google Scholar
• Nystrom T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in Type 2 diabetes patients with stable coronary artery disease. Am. J. Physiol. Endocrinol. Metab. 287(6), e1209–e1215 (2004).
   Google Scholar
• Courreges JP, Vilsboll T, Zdravkovic M et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes. Diabetic Med. 25(9), 1129–1131 (2008).
   Google Scholar
• Liu H, Dear AE, Knudsen LB, Simpson RW. A long-acting glucagon-like peptide-1 analogue attenuates induction of plasminogen activator inhibitor type-1 and vascular adhesion molecules. J. Endocrinol. 201(1), 59–66 (2009).
   Google Scholar
• Guo N, Sun J, Chen H, Zhang H, Zhang Z, Cai D. Liraglutide prevents diabetes progression in prediabetic OLETF rats. Endocrine J. 60(1), 15–28 (2013).
   Google Scholar
• Lee YS, Park MS, Choung JS et al. Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes. Diabetologia 55(9), 2456–2468 (2012).
   Google Scholar
• Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 117(18), 2340–2350 (2008).
   Google Scholar
• Sonne DP, Engstrom T, Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9–36) amide against ischemia-reperfusion injury in rat heart. Regul. Pept. 146(1–3), 243–249 (2008).
   Google Scholar
• Ku HC, Chen WP, Su MJ. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn‑Schmiedebergs Arch. Pharmacol. 384(2), 197–207 (2011).
   Google Scholar
• Noyan-Ashraf MH, Momen MA, Ban K et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4), 975–983 (2009).
   Google Scholar
• Timmers L, Henriques JP, de Kleijn DP et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol. 53(6), 501–510 (2009).
   Google Scholar
• Lonborg J, Vejlstrup N, Kelbaek H et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33(12), 1491–1499 (2012).
   Google Scholar
• Shiraki A, Oyama J, Komoda H et al. The glucagon-like peptide 1 analog liraglutide reduces TNF-alpha-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis 221(2), 375–382 (2012).
   Google Scholar
• Ceriello A, Esposito K, Testa R, Bonfigli AR, Marra M, Giugliano D. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an “endothelial resistance” to glucagon-like peptide 1 in diabetes. Diabetes Care 34(3), 697–702 (2011).
   Google Scholar
• Koska J. Incretins and preservation of endothelial function. Cardiovasc. Hematol. Agents Med. Chem. 10(4), 295–308 (2012).
   Google Scholar
• Verge D, Lopez X. Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in Type 2 diabetes. Curr. Diabetes Rev. 6(4), 191–200 (2010).
   Google Scholar
• Villanueva-Penacarrillo ML, Marquez L, Gonzalez N, Diaz-Miguel M, Valverde I. Effect of GLP-1 on lipid metabolism in human adipocytes. Hormone Metab. Res. 33(2), 73–77 (2001).
   Google Scholar
• Bertin E, Arner P, Bolinder J, Hagstrom-Toft E. Action of glucagon and glucagon-like peptide-1-(7–36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J. Clin. Endocrinol. Metab. 86(3), 1229–1234 (2001).
   Google Scholar
• Yan P, Li L, Yang M et al. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with Type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 92(3), 368–374 (2011).
   Google Scholar
• Inoue K, Maeda N, Kashine S et al. Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with Type 2 diabetes. Cardiovasc. Diabetol. 10, 109 (2011).
   Google Scholar
• Ansar S, Koska J, Reaven PD. Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc. Diabetol. 10, 61 (2011).
   Google Scholar
• Qin X, Shen H, Liu M et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 288(5), G943–G949 (2005).
   Google Scholar
• Hsieh J, Longuet C, Baker CL et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 53(3), 552–561 (2010).
   Google Scholar
• Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset Type 2 diabetes mellitus. Atherosclerosis 212(1), 217–222 (2010).
   Google Scholar
• Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes. Diabetes Care 30(6), 1608–1610 (2007).
   Google Scholar
• Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P. Exenatide therapy in obese patients with Type 2 diabetes mellitus treated with insulin. Endocrine Prac. 13(5), 444–450 (2007).
   Google Scholar
• Varanasi A, Bellini N, Rawal D et al. Liraglutide as additional treatment for Type 1 diabetes. Eur. J. Endocrinol. 165(1), 77–84 (2011). Demonstrates the effects of liraglutide (in combination with oral antidiabetic agents or insulin) on cardiovascular risk factors in patients with Type 2 diabetes.
   Google Scholar
• Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P. Clinical use of liraglutide in Type 2 diabetes and its effects on cardiovascular risk factors. Endocrine Prac. 18(2), 140–145 (2012).
   Google Scholar
• Li L, Miao Z, Liu R, Yang M, Liu H, Yang G. Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism. Mol. Med. 17(11–12), 1168–1178 (2011).
   Google Scholar
• Zinman B, Schmidt WE, Moses A, Lund N, Gough S. Achieving a clinically relevant composite outcome of an HbA1c of <7% without weight gain or hypoglycaemia in Type 2 diabetes: a meta-analysis of the liraglutide clinical trial programme. Diabetes Obes. Metab. 14(1), 77–82 (2012). Systematic review and meta-analysis evaluating liraglutide with commonly used therapies for Type 2 diabetes: glimepiride, rosiglitazone, glargine, exenatide, sitagliptin or placebo.
   Google Scholar
• Deacon CF, Mannucci E, Ahren B. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with Type 2 diabetes – a review and meta analysis. Diabetes Obes. Metab. 14(8), 762–767 (2012).
   Google Scholar
• Burgmaier M, Heinrich C, Marx N. Cardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes? Diabetic Med. 30(3), 289–299 (2012).
   Google Scholar
• Plutzky J, Garber A, Toft AD, Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in Type 2 diabetes. Diabetologia 52(Suppl. 1), S229 (2009).
   Google Scholar
• Kesavadev J, Shankar A, Krishnan G, Jothydev S. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with Type 2 diabetes in real world setting. Int. J. Gen. Med. 5, 317–322 (2012).
   Google Scholar
• Frost G, Leeds AA, Dore CJ, Madeiros S, Brading S, Dornhorst A. Glycaemic index as a determinant of serum HDL-cholesterol concentration. Lancet 353(9158), 1045–1048 (1999).
   Google Scholar
• Forsythe CE, Phinney SD, Feinman RD et al. Limited effect of dietary saturated fat on plasma saturated fat in the context of a low carbohydrate diet. Lipids 45(10), 947–962 (2010).
   Google Scholar
• Muller JE, Strater-Muller D, Marks HJ et al. Carbohydrate restricted diet in conjunction with metformin and liraglutide is an effective treatment in patients with deteriorated Type 2 diabetes mellitus: proof-of-concept study. Nutr. Metab. 8(1), 92 (2011). Proof-of-concept study showing the effects of a carbohydrate restriction diet in conjunction with metformin and liraglutide on metabolic control in patients with Type 2 diabetes.
   Google Scholar
• Astrup A, Carraro R, Finer N et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int. J. Obes. (Lond.) 36(6), 843–854 (2012).
   Google Scholar
• Yanai H, Hamasaki H, Adachi H, Moriyama S, Hirowatari Y. Effects of liraglutide, a human glucagon-like peptide-1 analog, on glucose/lipid metabolism, and adipocytokines in patients with Type 2 diabetes. J. Endocrinol. Metab. 1(3), 149–151 (2011).
   Google Scholar
• Rizvi AA, Montalto G, Patti AM, Rizzo M. Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. Expert Rev. Endocrinol. Metab. 7(4), 415–417 (2012).
   Google Scholar
• Rizzo M, Berneis K. Who needs to care about small, dense low-density lipoproteins? Int. J. Clin. Prac. 61(11), 1949–1956 (2007).
   Google Scholar
• Rizzo M, Rini GB, Berneis K. The clinical relevance of LDL size and subclasses modulation in patients with Type-2 diabetes. Exp. Clin. Endocrinol. Diabetes 115(8), 477–482 (2007).
   Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr. Vasc. Pharmacol. 9(5), 531–532 (2011).
   Google Scholar
• Mikhailidis DP, Elisaf M, Rizzo M et al. “European panel on low density lipoprotein (LDL) subclasses”: a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses. Curr. Vasc. Pharmacol. 9(5), 533–571 (2011).
   Google Scholar
• Yabe D, Seino Y. Liraglutide in adults with Type 2 diabetes: global perspective on safety, efficacy and patient preference. Clinical medicine insights. Endocrinol. Diab. 4, 47–62 (2011).
   Google Scholar
• Rizzo M, Rizvi AA, Spinas GA, Rini GB, Berneis K. Glucose lowering and antiatherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opin. Invest. Drugs 18(10), 1495–1503 (2009).
   Google Scholar
• Vilsboll T, Christensen M, Junker AE, Knop FK, Gluud LL. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ 344, D7771 (2012).
   Google Scholar
• Rizzo M, Patti A, Di Bartolo V, Giglio R, Montalto G, Rizvi A. Effect of liraglutide on carotid intima-media thickness in patients with Type 2 diabetes: a 4-month prospective study. Presented at: The 72nd Scientific Sessions of the American Diabetes Association. PA, USA, 8–12 June 2012.
   Google Scholar
• Rizzo M, Li Volti G, Patti A et al. Effects of liraglutide on plasma ghrelin concentrations and oxidative stress in patients with Type 2 diabetes: a 2-month prospective pilot study. Presented at: The 48th Annual Meeting of the European Association for the Study of Diabetes. Berlin, Germany, 1–5 October 2012.
   Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocrine Rev. 33(2), 187–215 (2012).
   Google Scholar
• Brown DX, Evans M. Choosing between GLP-1 receptor agonists and DPP-4 inhibitors: a pharmacological perspective. J. Nutr. Metab. 381713 (2012).
   Google Scholar
• Armstrong MJ, Houlihan DD, Rowe IA et al. Safety and efficacy of liraglutide in patients with Type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment. Pharmacol. Ther. 37(2), 234–242 (2013).
   Google Scholar